复旦张江 (688505.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−85.9x

Market Cap

CNY 8.69B

MomentumView details →

1D Return

−3.01%

YTD Return

—

RSI (14)

46.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−85.9x

Market Cap

CNY 8.69B

RSI (14)

46.6

MomentumView details →

1D Return

−3.01%

YTD Return

—

ProfitabilityView details →

Gross Margin

89.99%

Net Margin

−23.27%

EBITDA Margin

−12.64%

ROE (TTM)

−7.18%

ROA (TTM)

−6.50%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

−11.69%

EPS YoY

—

FCF YoY

+202.50%

Revenue CAGR 3Y

−12.71%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

7.46x

Quick Ratio

7.28x

Div Yield

—

Div Rate

—

Div Growth 1Y

−66.67%

Financials snapshotView financials →

Revenue (TTM)

654.94M

Net Income (TTM)

−152.39M

Op. CF (TTM)

127.86M

Latest newsMore news →

Fudan Zhangjiang Bio-Pharmaceutical reported interim results for the six months ended June 2026, with net profit of 36.895 million RMB, up 545% year-on-year.21d ago

Similar companies

美诺华603538.SH SSY Group Limited02005.HK 华北制药600812.SH 太极集团600129.SH 马应龙600993.SH 上海谊众688091.SH Find similar companies →

Latest newsMore news →

Fudan Zhangjiang Bio-Pharmaceutical reported interim results for the six months ended June 2026, with net profit of 36.895 million RMB, up 545% year-on-year.21d ago